logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Natalizumab (subcutaneous injection) for highly active relapsing remitting multiple sclerosis

< Back

Natalizumab (subcutaneous injection) for highly active relapsing remitting multiple sclerosis

Drugs

Neurology and Neurosurgery

March 2021


Natulizumab administered as a subcutaneous formulation is currently in clinical development for highly active relapsing remitting multiple sclerosis (RRMS). RRMS is characterised by periods of exacerbation of symptoms (relapses) followed by unpredictable periods of stability (remission). Highly active disease is characterised by an unchanged/increased relapse rate or by ongoing severe relapses compared with the previous year. Natalizumab is currently administered intravenously for patients with multiple sclerosis, however subcutaneous natalizumab injections require less time and are easier to perform.

Natalizumab is a type of biologic drug which binds to immune cells in the blood stream, preventing them from passing from the blood into the central nervous system where they can damage nerves. If licensed, subcutaneous natalizumab will offer more convenient treatment option for patients with highly active RRMS.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts